Project IV is new and based on novel cell and transgenic (Tg) mouse models of alpha-synuclein (a-syn) Lewy bodies (LBs) and neurites (LNs) which we hypothesize mediate neurodegeneration in Parkinson's disease without (PD) and with dementia (PDD) as well as in dementia with LBs (DLB). Project IV examines mechanisms of pathological a-syn transmission in the human A53T a-syn Tg mice (M83 line) that model LB disease (LBD)-like a-syn pathology, and assesses the efficacy of passive immunotherapy to abrogate transmission of a-syn pathologies. Project III has defined two stains (A and B) of a-syn pre-formed fibrils (PFFs), and injections of strain A a-syn PFFs into striatum and cortex of young human M83 mice accelerated the widespread formation of LBs/LNs as well as onset of neurological symptoms, and this was associated with a dramatic reduction in the lifespan of injected M83 mice. The propagation of pathologic a-syn to widespread central nervous system (CNS) regions is consistent with transynaptic cell-to-cell passage of a-syn pathology. Injections of brain lysates containing pathological a-syn from 12-14 month old diseased M83 mice into young disease free M83 mice also had the same effects as synthetic a-syn PFFs indicating that a-syn PFFs alone induce PD-like pathology and transmit disease. These findings open up new avenues for understanding the progression of PD/PDD/DLB and provide fresh opportunities to develop novel therapies for LBD. Project IV aligns with the overall theme of the Penn Udall Center and collaborates with all Cores/Projects to elucidate mechanisms underlying the progression of LBD to dementia. The overarching hypothesis to be tested here is that different pathological species or strains of a-syn generated synthetically or isolated from different postmortem brain regions of PD/PDD/DLB patients transmit disease in distinct ways that reflect intrinsic properties of the different pathological a-syn strains. To that end, the Specific Aims of Project IV are:
Aim 1 : To determine if synthetic a-syn PFF strains A and B characterized by Project III differentially transmit LBD following injections into the brains of M83 mice using methods to assess the behavior, neuropathology and cerebrospinal fluid (CSF) levels of a-syn;
Aim 2 : To determine if lysates enriched in LBs/LNs from PD substantia nigra versus PDD/DLB cingulate cortex contain different a-syn strains that differentially transmit LBD following injections into the brains of M83 mice using the same methods as in Aim 1;
Aim 3 : To conduct proof of concept (POC) studies in M83 mice injected with pathological a-syn to determine if passive immunization with epitope specific anti-a-syn monoclonal antibodies identified by Project III to neutralize a-syn transmission, will abrogate induction and spread of a-syn pathology in vivo.

Public Health Relevance

Completion of these studies will significantly advance understanding of mechanisms whereby pathological species of a-syn induce and transmit PD/PDD/DLB-like pathology in animal models. These findings will have significant translational impact on efforts to develop biomarkers and novel immune therapies for PD/PDD/DLB and related a-synucleinopathies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS053488-08
Application #
8705043
Study Section
Special Emphasis Panel (ZNS1-SRB-J)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
8
Fiscal Year
2014
Total Cost
$274,735
Indirect Cost
$103,031
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brennan, Laura; Siderowf, Andrew; Rubright, Jonathan D et al. (2016) The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. Parkinsonism Relat Disord 25:21-6
Fullard, Michelle E; Tran, Baochan; Xie, Sharon X et al. (2016) Olfactory impairment predicts cognitive decline in early Parkinson's disease. Parkinsonism Relat Disord 25:45-51
Roalf, David R; Moore, Tyler M; Wolk, David A et al. (2016) Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease. J Neurol Neurosurg Psychiatry :
Brettschneider, J; Irwin, D J; Boluda, S et al. (2016) Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type. Neuropathol Appl Neurobiol :
Biundo, Roberta; Weis, L; Bostantjopoulou, S et al. (2016) MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm (Vienna) 123:431-8
Lim, Nicholas S; Swanson, Christine R; Cherng, Hua-Ren et al. (2016) Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. Ann Clin Transl Neurol 3:346-55
Price, Amy Rose; Peelle, Jonathan E; Bonner, Michael F et al. (2016) Causal Evidence for a Mechanism of Semantic Integration in the Angular Gyrus as Revealed by High-Definition Transcranial Direct Current Stimulation. J Neurosci 36:3829-38
Chahine, Lama M; Weintraub, Daniel; Hawkins, Keith A et al. (2016) Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Mov Disord 31:86-94
Tuttle, Marcus D; Comellas, Gemma; Nieuwkoop, Andrew J et al. (2016) Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. Nat Struct Mol Biol 23:409-15
White, Matthew T; Shaw, Leslie M; Xie, Sharon X et al. (2016) Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease. J Alzheimers Dis 51:463-70

Showing the most recent 10 out of 250 publications